<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165672</url>
  </required_header>
  <id_info>
    <org_study_id>E3810-J081-462</org_study_id>
    <nct_id>NCT00165672</nct_id>
  </id_info>
  <brief_title>A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease</brief_title>
  <official_title>A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To investigate esophageal reflux condition in patients with non-erosive gastroesophageal
      reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week
      treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent Time With pH &lt;4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Mean and standard deviation of percent time pH&lt;4.0 on 24 hour esophageal pH monitoring.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Non-erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RABEPRAZOLE SODIUM</intervention_name>
    <description>rabeprazole sodium 5 mg: once daily orally for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RABEPRAZOLE SODIUM</intervention_name>
    <description>rabeprazole sodium 10 mg: once daily orally for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patients to be included will be outpatients who meet all of the following criteria. No
        specific gender is asked.

        &lt;For the observation period&gt;

          1. Patients who have &quot;heartburn&quot; 2 days a week or more during consecutive 3 weeks* prior
             to pre-observation screening. *If a day of screening and a day of starting observation
             (date of registration) are different, heartburn must continuously be present during
             the in-between period.

          2. Patients who meet both 1) and 2) below;

        1) The symptom is a burning sensation arising from the stomach or the lower chest.

        2) The symptom tends to appear frequently or is aggravated after eating, when bending a
        body forward, and/or when pressing on the abdomen.

        3. Patients categorized in &quot;grade M&quot; (discoloring type: minimal change) according to the
        Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.

        4. Patients who are 20 years old or older at the time of obtaining consent.

        5. Patients who are informed of the objective and details of this study and give written
        consent for study entry.

        &lt;For the treatment period&gt;

          1. Patients who have &quot;heartburn&quot; 2 days a week or more during 7 days until the treatment
             period (during the observation period).

          2. Patients with &quot;heartburn diary&quot; that is completely filled out during 7 days until the
             treatment period (during the observation period). If the observation period is 8 days
             or longer, those with a heartburn diary of which entries are fulfilled 80% or more
             during the observation period.

          3. Patients with 80% or better drug compliance for antacids during the observation
             period.

          4. Patients whose percentage of time showing pH&lt;4.0 (% time pH&lt;4.0) is not 0%* during the
             24-hour esophageal pH monitoring at the end of observation period (at the beginning of
             treatment period). *If parameters calculated from analytical program show 0.0% after
             round-off, this patient cannot be entered into the treatment period.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study.

          1. Patients who cannot keep adequate entries of a heartburn diary by themselves.

          2. Patients who strongly complain &quot;feeling of heavy stomach&quot; and/or &quot;abdominal bloating.&quot;

          3. Patients who have a complication or history of psychiatric or psychosomatic disease
             (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those
             who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic
             treatment).

          4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6
             months* have elapsed from the end of H. pylori eradication therapy to the beginning of
             the observation period. *: The same day 6 months earlier, and the day at the end of 6
             months earlier if it is at the end of month.

          5. Patients with open gastric or duodenal ulcer.

          6. Patients with acute gastritis.

          7. Patients with a history of any surgical intervention that affect peptic secretion
             (e.g., upper gastrointestinal tract resection and/or vagotomy).

          8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.

          9. Patients with scleroderma.

         10. Patients with a history or complication of angina pectoris.

         11. Patients who work at night (working for a night-shift).

         12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to
             pre-observation screening.

         13. Patients who need non steroidal anti-inflammatory drugs (NSAIDs) (except topical
             preparations), steroids (except topical preparations), and/or aspirin treatment every
             day.

         14. Patients receiving dialysis therapy.

         15. Patients with a serious complication such as cardiovascular disease (myocardial
             infarction, etc.), hematological disorder (e.g, aplastic anemia), renal disease (e.g.,
             acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant
             tumor.

         16. Patients with known hypersensitivity to antacids or PPIs.

         17. Patients who are pregnant or those with childbearing potential, or those who wish to
             become pregnant or are lactating during the study period.

         18. Patients receiving another investigational drug or those who received another
             investigational drug within 6 months prior to pre-observation screening* *:
             Registration is allowed on the same day of 6 months earlier, and the day at the end of
             6 months earlier if it is at the end of month.

         19. Patients who are judged to be ineligible for the study entry by the investigator or
             subinvestigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Sugisaki</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi-Prefecture</state>
        <zip>467-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <state>Fukuoka-Prefecture</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <state>Fukuoka-Prefecture</state>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yukuhashi</city>
        <state>Fukuoka-Prefecture</state>
        <zip>824-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <state>Hiroshima-Prefecture</state>
        <zip>734-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Osaka-Prefecture</state>
        <zip>530-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Osaka-Prefecture</state>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <state>Saga-Prefecture</state>
        <zip>849-0937</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otsu</city>
        <state>Shiga-Prefecture</state>
        <zip>520-2121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <state>Shimane-Prefecture</state>
        <zip>693-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>755-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>September 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2011</results_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nobuyuki Sugisaki</name_title>
    <organization>Eisai Co., Ltd.</organization>
  </responsible_party>
  <keyword>24-hour esophageal pH monitoring</keyword>
  <keyword>non-erosive gastroesophageal reflux disease</keyword>
  <keyword>NERD</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>rabeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was recruited at 13 centers in Japan during the period of May-2005 to Oct-2005.</recruitment_details>
      <pre_assignment_details>Antacid was administered 1-2 weeks for observational period (non-blind). Patients showing the resistance to antacid and patients for whom percent time with pH &lt;4.0 &gt;0% during the 24 hour esophageal pH monitoring at the end of the observation period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>E3810 Pariet (Rabeprazole Sodium) 5 mg</title>
          <description>E3810 5 mg: once daily orally for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>E3810 Pariet (Rabeprazole Sodium) 10 mg</title>
          <description>E3810 10 mg: once daily orally for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>E3810 Pariet (Rabeprazole Sodium) 5 mg</title>
          <description>E3810 5 mg: once daily orally for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>E3810 Pariet (Rabeprazole Sodium) 10 mg</title>
          <description>E3810 10 mg: once daily orally for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>This number is the population for data analysis of clinical pharmacology.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="20.0"/>
                    <measurement group_id="B2" value="42.7" spread="15.8"/>
                    <measurement group_id="B3" value="41.6" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent Time With pH &lt;4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).</title>
        <description>Mean and standard deviation of percent time pH&lt;4.0 on 24 hour esophageal pH monitoring.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>The major endpoint of this study was analysed in the population for clinical pharmacology data (observation period and treatment period)</population>
        <group_list>
          <group group_id="O1">
            <title>E3810 Pariet (Rabeprazole Sodium) 5 mg</title>
            <description>E3810 5 mg: once daily orally for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>E3810 Pariet (Rabeprazole Sodium) 10 mg</title>
            <description>E3810 10 mg: once daily orally for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Time With pH &lt;4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).</title>
          <description>Mean and standard deviation of percent time pH&lt;4.0 on 24 hour esophageal pH monitoring.</description>
          <population>The major endpoint of this study was analysed in the population for clinical pharmacology data (observation period and treatment period)</population>
          <units>Percent Time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.72" spread="5.30"/>
                    <measurement group_id="O2" value="7.03" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.79"/>
                    <measurement group_id="O2" value="0.87" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>E3810 Pariet (Rabeprazole Sodium) 5 mg</title>
          <description>E3810 5 mg: once daily orally for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>E3810 Pariet (Rabeprazole Sodium) 10 mg</title>
          <description>E3810 10 mg: once daily orally for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nobuyuki Sugisaki, Study Director</name_or_title>
      <organization>Eisai Co.,Ltd. Eisai Product Creation Systems</organization>
      <phone>+81-3-3817-3908</phone>
      <email>n-sugisaki@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

